Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athersys Inc ATHXQ

Healthcare Biotechnology
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage... see more

Recent & Breaking News (PINL:ATHXQ)

Athersys Announces Successful Type B Meeting with the FDA

Business Wire March 22, 2023

Athersys Expands IP Protection with First New Patent for SIFU® Technology

Business Wire February 28, 2023

Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion

Business Wire February 14, 2023

Athersys to Host Business Update Conference Call on February 14th

Business Wire February 2, 2023

Athersys to Participate in International Stroke Conference and BioProcess International

Business Wire January 30, 2023

Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January

Business Wire January 11, 2023

Athersys Provides MultiStem Clinical Update

Business Wire January 9, 2023

Athersys Appoints Joseph Nolan to Its Board of Directors

Business Wire January 5, 2023

Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update

Business Wire November 15, 2022

Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.'s Biotech Conference

Business Wire November 11, 2022

Athersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offering

Business Wire November 10, 2022

Athersys Reschedules Third Quarter Conference Call to November 15

Business Wire November 10, 2022

Athersys, Inc. Announces Pricing of $5.5 Million Public Offering

Business Wire November 9, 2022

Athersys, Inc. Announces Proposed Public Offering

Business Wire November 7, 2022

Athersys to Host Third Quarter Financial Results Call

Business Wire October 25, 2022

Athersys to Present at 2022 Cell & Gene Meeting on the Mesa Conference and Attend 14th World Stroke Congress in October

Business Wire October 4, 2022

Athersys to Host Business Update Conference Call on October 6th

Business Wire September 30, 2022

Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering

Business Wire September 23, 2022

Athersys Announces 1-for-25 Reverse Stock Split

Business Wire August 25, 2022

Athersys, Inc. Announces Closing of $12 Million Registered Direct Offering

Business Wire August 17, 2022